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SUMMARY: The Nuclear Regulatory 
Commission (NRC) is amending its 
regulations regarding the medical use of 
byproduct material. The direct final rule 
will clarify the definitions of authorized 
users, authorized medical physicists, 
authorized nuclear pharmacists, and 
radiation safety officers; clarify the 
notification requirements if the patient 
is in a medical emergency or dies; 
clarify the recordkeeping requirements 
for calibration of brachytherapy sources; 
correct the title for the National Institute 
of Standards and Technology; clarify 
that prior to October 24, 2004, 
individuals who meet the training and 
experience requirements in Subpart J 
may undertake responsibilities specified 
in certain sections in Subparts B and D–
H; and eliminate a restriction that 
training for ophthalmic use of 
strontium-90 can only be conducted in 
medical institutions. These amendments 
are necessary to clarify certain 
inconsistencies within the regulations 
and to allow training in ophthalmic 
treatment to be conducted in eye clinics 
or private practices, in addition to 
medical institutions.
DATES: The final rule is effective on July 
7, 2003 unless significant adverse 
comments are received by May 21, 2003.
ADDRESSES: You may submit comments 
by any one of the following methods. 
Please include the following number 
(RIN 3150–AHO8) in the subject line of 
your comments. Comments on 
rulemakings submitted in writing or in 
electronic form will be made available 
to the public in their entirety on the 
NRC rulemaking Web site. Personal 
information will not be removed from 
your comments. 
Mail comments to: Secretary, U.S. 
Nuclear Regulatory Commission, 
Washington, DC 20555–0001, ATTN: 
Rulemakings and Adjudications Staff. 
E-mail comments to: SECY@nrc.gov. If 
you do not receive a reply e-mail 
confirming that we have received your 
comments, contact us directly at (301) 
415–1966. You may also submit 
comments via the NRC’s rulemaking 
Web site at http://ruleforum.llnl.gov. 
Address questions about our rulemaking 
Web site to Carol Gallagher (301) 415–
5905; email cag@nrc.gov. 
Hand deliver comments to: 11555 
Rockville Pike, Rockville, Maryland 
20852, between 7:30 a.m. and 4:15 p.m. 
Federal workdays. (Telephone (301) 
415–1966). 
Fax comments to: Secretary, U.S. 
Nuclear Regulatory Commission at (301) 
415–1101. 
Publicly available documents related 
to this rulemaking may be examined 
and copied for a fee at the NRC’s Public 
Document Room (PDR), Public File Area 
O1 F21, One White Flint North, 11555 
Rockville Pike, Rockville, Maryland. 
Selected documents, including 
comments, can be viewed and 
downloaded electronically via the NRC 
rulemaking web site at http://
ruleforum.llnl.gov. 
Publicly available documents created 
or received at the NRC after November 
1, 1999, are available electronically at 
the NRC’s Electronic Reading Room at 
http://www.nrc.gov/NRC/ADAMS/
index.html. From this site, the public 
can gain entry into the NRC’s 
Agencywide Document Access and 
Management System (ADAMS), which 
provides text and image files of NRC’s 
public documents. If you do not have 
access to ADAMS or if there are 
problems in accessing the documents 
located in ADAMS, contact the NRC 
Public Document Room (PDR) Reference 
staff at 1–800–397–4209, 301–415–4737 
or by e-mail to pdr@nrc.gov.
FOR FURTHER INFORMATION CONTACT: Dr. 
Anthony N. Tse, Office of Nuclear 
Material Safety and Safeguards, U.S. 
Nuclear Regulatory Commission, 
Washington, DC 20555–0001, telephone 
(301) 415–6233, e-mail: ant@nrc.gov.
SUPPLEMENTARY INFORMATION: 
Procedural Information 
Because NRC considers this action to 
be noncontroversial, the NRC is using 
the direct final rule process for this rule. 
The amendments in this rule will 
become effective on July 7, 2003. 
However, if the NRC receives significant 
adverse comments on this direct final 
rule by May 21, 2003, then the NRC will 
publish a document that withdraws this 
action and will subsequently address 
the comments received in a final rule as 
a response to the companion proposed 
rule published elsewhere in this Federal 
Register. Absent significant 
modifications to the proposed revisions 
requiring republication, the NRC will 
not initiate a second comment period on 
this action. 
A significant adverse comment is a 
comment where the commenter 
explains why the rule would be 
inappropriate, including challenges to 
the rule’s underlying premise or 
approach, or would be ineffective or 
unacceptable without a change. A 
comment is adverse and significant if: 
(1) The comment opposes the rule and 
provides a reason sufficient to require a 
substantive response in a notice-and-
comment process. For example, a 
substantive response is required when— 
(A) The comment causes the staff to 
reevaluate (or reconsider) its position or 
conduct additional analysis; 
(B) The comment raises an issue 
serious enough to warrant a substantive 
response to clarify or complete the 
record; or 
(C) The comment raises a relevant 
issue that was not previously addressed 
or considered by the staff. 
(2) The comment proposes a change 
or an addition to the rule and it is 
apparent that the rule would be 
ineffective or unacceptable without 
incorporation of the change or addition. 
(3) The comment causes the staff to 
make a change (other than editorial) to 
the rule. 
Background
The NRC published in the Federal 
Register a final rule amending 10 CFR 
part 35 regarding medical use of 
byproduct material on April 24, 2002 
(67 FR 20249) (final rule). Subsequently, 
the NRC staff (staff) identified 
typographical and editorial errors as 
well as inconsistencies in the Part 35 
final rule. The staff published a 
document correcting the typographical 
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and editorial errors on October 9, 2002 
(67 FR 62872). Both the final rule and 
the correction became effective on 
October 24, 2002. This amendment 
addresses certain inconsistencies that 
have been identified in the Part 35 final 
rule and implements a minor change to 
eliminate a restriction that training for 
ophthalmic use of strontium-90 can 
only be conducted in a medical 
institution. 
Section-by-Section Analysis 
(1) Section 35.2, Definitions. In this 
section, ‘‘Authorized medical physicist’’ 
(AMP), ‘‘Authorized nuclear 
pharmacist’’ (ANP), ‘‘Authorized user’’ 
(AU), and ‘‘Radiation Safety Officer’’ 
(RSO) are defined as individuals who 
meet the criteria in certain referenced 
sections of this final rule. However, the 
staff has specifically reinserted subpart 
J (as contained in the proposed rule (63 
FR 43516; August 13, 1998)) for a two-
year transition period. Therefore, until 
October 24, 2004, individuals certified 
by medical boards listed in that subpart 
are also qualified as authorized users. It 
is inconsistent to recognize as 
authorized users individuals who meet 
Subpart J requirements, but not include 
them in the relevant definitions in 
§35.2. 
The definition of AU is therefore 
amended to include individuals 
qualified under §§35.910(a), 35.920(a), 
35.930(a), 35.940(a), 35.950(a) and 
35.960(a), until October 24, 2004. 
Similarly, the definitions of AMP, ANP, 
and RSO are amended to include 
individuals authorized pursuant to 
§§35.961(a) and (b), 35.980(a), and 
35.900(a), respectively. 
(2) Section 35.51, Training for an 
authorized medical physicist. The 
second sentence in paragraph (b)(2) 
states: ‘‘The written certification must 
be signed by a preceptor authorized 
medical physicist who meets the 
requirements in §35.51 or equivalent 
Agreement State requirements.*** ’’ 
However, during the two-year transition 
period, an individual who meets the 
requirements of §35.961 in Subpart J is 
also qualified to be a preceptor 
authorized medical physicist. Therefore, 
this sentence is amended by replacing 
the phrase ‘‘in §35.51 or equivalent 
Agreement State requirement’’ with the 
phrase ‘‘in §35.51, or, before October 
24, 2004, §35.961, or equivalent 
Agreement State requirements.*** ’’ 
The following additional sections 
reflect similar inconsistencies: 
§§35.190(b), (c)(1)(ii), (c)(2); 35.290(b), 
(c)(1)(ii), (c)(2); 35.390(b)(1)(ii), (b)(2); 
35.392(b), (c)(2), (c)(3); 35.394(b), (c)(2), 
(c)(3); 35.490(b)(1)(ii), (b)(2), (b)(3); 
35.491(a), (b)(3); and 35.690(b)(1)(ii), 
(b)(2), (b)(3). Therefore, these sections 
are also amended to include the 
corresponding sections from subpart J. 
(3) Section 35.100, Use of unsealed 
byproduct material for uptake, dilution, 
and excretion studies for which a 
written directive is not required. 
Paragraph (b) states: ‘‘Prepared by an 
authorized nuclear pharmacist, a 
physician who is an authorized user and 
who meets the requirements specified in 
§§35.290 or 35.390, or an individual 
under the supervision of either as 
specified in §35.27.’’ However, during 
the two-year transition period, an 
authorized user who meets the 
requirements of §35.920 in Subpart J is 
also qualified to prepare unsealed 
byproduct material for medical use. 
Therefore, this sentence is amended by 
replacing the phrase ‘‘in §§35.290 or 
35.390’’ with the phrase ‘‘in §§35.290 or 
35.390, or, before October 24, 2004, 
§35.920.’’ In addition, the format of this 
paragraph has been modified to clearly 
identify the three categories of persons 
who can prepare unsealed byproduct 
material for medical use for uptake, 
dilution, or excretion. 
The following additional sections 
reflect similar inconsistencies: 
§§35.200(b) and 35.300(b). Therefore, 
these sections are also amended to 
include §35.920. 
(4) Section 35.310, Safety instruction. 
Paragraph (a)(5) provides that a licensee 
must notify ‘‘the’’ AU if the patient has 
a medical emergency or dies. However, 
corresponding sections for 
brachytherapy and external beam 
therapy (i.e., §§35.410(a)(5), 35.415(c), 
and 35.615(f)(4)) require that ‘‘an’’ AU, 
instead of ‘‘the’’ AU, be notified. Section 
III of the Supplementary Information in 
the April 24, 2002, final rule states: 
‘‘Therefore, because of the type of 
dosages that are administered under 
§35.300, we believe it is important that 
an AU be available to be contacted in 
case of a medical emergency or death.’’ 
Notifying ‘‘an’’ AU should meet this 
requirement because ‘‘the’’ AU who 
treats the patient may be unavailable 
when the patient has a medical 
emergency or dies. This section is 
revised to replace the words ‘‘the’’ AU 
with the words ‘‘an’’ AU. 
(5) Section 35.315, Safety precautions. 
Paragraph (b) provides that a licensee 
must notify the RSO, or his or her 
designee, and ‘‘the’’ AU if the patient 
has a medical emergency or dies. This 
section is modified to replace the words 
‘‘the’’ AU with the words ‘‘an’’ AU for 
the reasons explained in (4), above. 
(6) Section 35.432, Calibration 
measurements of brachytherapy sources. 
Paragraph (a) provides in part that a 
licensee shall determine the source 
output and source positioning accuracy. 
Paragraph (b) states that a licensee may 
use measurements provided by the 
source manufacturer or by a calibration 
laboratory. However, it is not clear that 
the licensee may perform its own 
measurement or, as an alternative, use 
measurements from manufacturer or 
calibration laboratory. For clarification, 
this section is therefore revised to add 
a phrase to the beginning of paragraph 
(b) to read as follows: ‘‘Instead of a 
licensee making its own measurements 
as required in (a), the licensee may use 
measurements provided by*** . ’’ 
(7) Section 35.491, Training for 
ophthalmic use of strontium-90. 
Paragraph (b)(2) currently provides in 
part that an authorized user of 
strontium-90 for ophthalmic 
radiotherapy must have completed 
supervised clinical training under the 
supervision of an authorized user at a 
medical institution that includes the use 
of strontium-90 for the ophthalmic 
treatment of five individuals. This 
current requirement unnecessarily 
excludes authorized users at eye clinics 
and private practices from being 
allowed to provide training. This 
restriction should be eliminated because 
many authorized users for ophthalmic 
treatment work in clinics or private 
practices. This section is therefore 
revised to add ‘‘clinic or private 
practice’’ to ‘‘medical institution’’ as 
acceptable locations where the requisite 
supervised clinical training may be 
provided. 
(8) Section 35.630. Paragraph (a)(1) 
states: ‘‘The system must have been 
calibrated using a system or source 
traceable to the National Institute of 
Science and Technology (NIST) 
a n d*** . ’’ The title of NIST is 
‘‘National Institute of Standards and 
Technology.’’ Thus, the word ‘‘Science’’ 
is replaced by the word ‘‘Standards.’’
(9) Section 35.2432, Records of 
calibration measurements of 
brachytherapy sources. This section 
provides that a licensee must maintain 
a record of the calibration of 
brachytherapy sources required by 
§35.432. Paragraph 35.2432(b)(5) 
requires that the record must include 
the signature of the authorized medical 
physicist (AMP). Section 35.432, 
Calibration measurements of 
brachytherapy sources, requires that a 
licensee shall have a brachytherapy 
source calibrated or the licensee may 
use measurements provided by the 
source manufacturer or by a calibration 
laboratory. However, §35.432 does not 
specify that an AMP must perform the 
calibration. Thus, it is inconsistent to 
require a record of the signature of the 
AMP in §35.2432 without a
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requirement for the AMP to perform the 
calibration in §35.432. 
In the proposed rule (63 FR 43516; 
August 13, 1998), §35.2432 would have 
provided that the record of calibration 
must contain ‘‘the name of the 
individual or the source manufacturer 
who performed the calibration.’’ This 
language was consistent with the 
language of proposed §35.432. 
In the final rule, (67 FR 20249; April 
24, 2002), §35.432 was changed from 
that in the proposed rule to allow the 
licensee to rely on measurements 
provided by a calibration laboratory, in 
addition to those provided by a 
manufacturer. The language in §35.2432 
was also changed but was not consistent 
with §35.432. 
The Supplementary Information to 
the final rule includes a discussion of 
the changes made to §35.2432 between 
the proposed rule and the final rule. 
That discussion does not include any 
rationale for changing the proposed rule 
language requiring ‘‘the name of the 
individual or the source manufacturer 
who performed the calibration’’ to the 
final rule language requiring ‘‘the 
signature of the authorized medical 
physicist.’’ Section 35.2432(b)(5) is 
therefore modified to replace the phrase 
‘‘the signature of the authorized medical 
physicist’’ with the phrase ‘‘the name of 
the individual, the source manufacturer, 
or the calibration laboratory who 
performed the calibration.’’ This 
modification resolves inconsistency 
between §35.2432 and §35.432. 
Agreement State Compatibility 
Under the ‘‘Policy Statement on 
Adequacy and Compatibility of 
Agreement State Programs’’ approved by 
the Commission on June 30, 1997, and 
published in the Federal Register on 
September 3, 1997 (62 FR 46517), this 
direct final rule is a matter of 
compatibility between NRC and the 
Agreement States, thereby providing 
consistency among Agreement State and 
NRC requirements. A Compatibility 
Category ‘‘B’’ designation means the 
requirement has significant direct 
transboundary implications. 
Compatibility Category ‘‘B’’ designated 
Agreement State requirements should be 
essentially identical to those of NRC. A 
Compatibility Category ‘‘D’’ designation 
means the requirement does not need to 
be adopted by an Agreement State for 
purposes of compatibility. The 
Compatibility Category Health and 
Safety (H&S) identifies requirements 
that are not required for compatibility, 
but which have particular health and 
safety significance. Agreement States 
should adopt the essential objectives of 
such requirements in order to maintain 
an adequate program. 
The Compatibility Categories for the 
sections amended in this direct final 
rule are the same as the sections in the 
current regulations. The revisions to 
§§35.2, 35.51, 35.190, 35.290, 35.390, 
35.392, 35.394, 35.490, 35.491, and 
35.690 are classified as Category B. The 
revisions to §§35.100, 35.200, 35.300, 
35.310(a), 35.315, and 35.630 are 
classified as Category H&S. The revision 
to §35.2432 is classified as Category D. 
Voluntary Consensus Standards 
The National Technology Transfer Act 
of 1995 (Pub. L. 104–113) requires that 
Federal agencies use technical standards 
that are developed or adopted by 
voluntary consensus standards bodies 
unless the use of such a standard is 
inconsistent with applicable law or 
otherwise impractical. In this direct 
final rule, NRC is amending 10 CFR part 
35 to clarify certain inconsistencies with 
the regulations and to allow training in 
ophthalmic treatment to be conducted 
in eye clinics or private practices, in 
addition to medical institutions. This 
action does not constitute the 
establishment of a standard that 
establishes generally-applicable 
requirements. 
Environmental Impact: Categorical 
Exclusion 
The Commission has determined that 
this direct final rule is the type of action 
described in categorical exclusion 10 
CFR 51.22(c)(2). Therefore, neither an 
environmental impact statement nor an 
environmental assessment has been 
prepared for this direct final rule. 
Paperwork Reduction Act Statement 
This direct final rule does not contain 
a new or amended information 
collection requirement subject to the 
Paperwork Reduction Act of 1995 (44 
U.S.C. 3501 et seq.). However, the rule 
makes a technical change to correct an 
error in a record requirement that 
appeared in the Part 35 final rule. 
Existing requirements were approved by 
the Office of Management and Budget, 
approval number 3150–0010. 
Public Protection Notification 
If a means used to impose an 
information collection does not display 
a currently valid OMB control number, 
NRC may not conduct or sponsor, and 
a person is not required to respond to, 
the information collection. 
Regulatory Analysis 
A regulatory analysis has not been 
prepared for this direct final rule. The 
clarifying amendments are for ease of 
understanding of certain aspects of part 
35. The minor amendment on 
ophthalmic treatment is to provide 
flexibility that clinical training can be 
conducted under supervision of an 
authorized user in clinics or private 
practices, in addition to medical 
institutions. This flexibility could 
potentially result in a small reduction in 
burden for an individual who is 
undertaking the clinic training. 
Regulatory Flexibility Certification 
In accordance with the Regulatory 
Flexibility Act of 1980, 5 U.S.C. 605(b), 
NRC certifies that this rule will not, if 
promulgated, have a significant 
economic impact on a substantial 
number of small entities. This direct 
final rule simply amends present 
regulations to clarify certain 
inconsistencies with the regulations and 
to allow training in ophthalmic 
treatment to be conducted in eye clinics 
or private practices, in addition to 
medical institutions. The companies 
that own these facilities do not fall 
within the scope of the definition of 
‘‘small entities’’ set forth in the 
Regulatory Flexibility Act or the size 
standards adopted by NRC (10 CFR 
2.810). 
Backfit Analysis 
NRC has determined that the backfit 
rule does not apply to this direct final 
rule because these amendments do not 
involve any provisions that would 
impose backfits as defined in 10 CFR 
Chapter 1. 
Small Business Regulatory Enforcement 
Fairness Act 
In accordance with the Small 
Business Regulatory Enforcement 
Fairness Act of 1996, NRC has 
determined that this action is not a 
major rule and has verified this 
determination with the Office of 
Information and Regulatory Affairs, 
Office of Management and Budget.
List of Subjects in 10 CFR Part 35 
Byproduct material, Criminal 
penalties, Drugs, Health facilities, 
Health professions, Medical devices, 
Nuclear materials, Occupational safety 
and health, Radiation protection, 
Reporting and recordkeeping 
requirements.
 For reasons set out in the preamble and 
under the authority of the Atomic Energy 
Act of 1954, as amended; the Energy 
Reorganization Act of 1974, as amended; 
and 5 U.S.C. 552 and 553; NRC is 
adopting the following amendments to 
10 CFR part 35.
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PART 35—MEDICAL USE OF 
BYPRODUCT MATERIAL
 1. The authority citation for Part 35 
continues to read as follows:
Authority: Secs. 81, 161, 182, 183, 68 Stat. 
935, 948, 953, 954, as amended (42 U.S.C. 
2111, 2201, 2232, 2233); sec. 201, 88 Stat. 
1242, as amended (42 U.S.C. 5841).
 2. In §35.2, the definitions for author-
ized medical physicist, authorized 
nuclear pharmacist, authorized user, 
and radiation safety officer, are amended 
by revising paragraph (1) of each defini-
tion to read as follows:
§35.2 Definitions.
* * * * *
Authorized medical physicist means 
an individual who— 
(1) Meets the requirements in 
§§35.51(a) and 35.59; or, before October 
24, 2004, meets the requirements in 
§§35.961(a), or (b), and 35.59; or
* * * * *
Authorized nuclear pharmacist means 
a pharmacist who— 
(1) Meets the requirements in 
§§35.55(a) and 35.59; or, before October 
24, 2004, meets the requirements in 
§§35.980(a) and 35.59; or
* * * * *
Authorized user means a physician, 
dentist, or podiatrist who— 
(1) Meets the requirements in §§35.59 
and 35.190(a), 35.290(a), 35.390(a), 
35.392(a), 35.394(a), 35.490(a), 
35.590(a), or 35.690(a); or, before 
October 24, 2004, meets the 
requirements in §§35.910(a), 35.920(a), 
35.930(a), 35.940(a), 35.950(a), or 
35.960(a) and 35.59; or
* * * * *
Radiation Safety Officer means an 
individual who— 
(1) Meets the requirements in 
§§35.50(a) and 35.59; or, before October 
24, 2004, meets the requirements in 
§§35.900(a) and 35.59; or
* * * * *
 3. In §35.51, the second sentence of 
paragraph (b)(2) is revised to read as fol-
lows:
§35.51 Training for an authorized medical 
physicist.
* * * * *
(b) * * * 
(2) * * * The written certification 
must be signed by a preceptor 
authorized medical physicist who meets 
the requirements in §35.51, or, before 
October 24, 2004, §35.961, or 
equivalent Agreement State 
requirements for an authorized medical 
physicist for each type of therapeutic 
medical unit for which the individual is 
requesting authorized medical physicist 
status.
 4. In §35.100, paragraph (b) is revised 
to read as follows:
§35.100 Use of unsealed byproduct 
material for uptake, dilution, and excretion 
studies for which a written directive is not 
required.
* * * * *
(b) Prepared by: 
(1) An authorized nuclear pharmacist; 
(2) A physician who is an authorized 
user and who meets the requirements 
specified in §§35.290, 35.390, or, before 
October 24, 2004, §35.920; or 
(3) An individual under the 
supervision, as specified in §35.27, of 
the authorized nuclear pharmacist in 
paragraph (b)(1) of this section or the 
physician who is an authorized user in 
paragraph (b)(2) of this section; or
* * * * *
 5. In §35.190, paragraph (b), the 
introductory text of paragraph (c)(1)(ii), 
and paragraph (c)(2) are revised to read 
as follows:
§35.190 Training for uptake, dilution, and 
excretion studies.
* * * * *
(b) Is an authorized user under 
§§35.290, 35.390, or, before October 24, 
2004, §§35.910, 35.920, or 35.930, or 
equivalent Agreement State 
requirements; or
* * * * *
(c) * * * 
(1) * * * 
(ii) Work experience, under the 
supervision of an authorized user who 
meets the requirements in §§35.190, 
35.290, 35.390, or, before October 24, 
2004, §§35.910, 35.920, or 35.930, or 
equivalent Agreement State 
requirements, involving—
* * * * *
(2) Has obtained written certification, 
signed by a preceptor authorized user 
who meets the requirements in 
§§35.190, 35.290, 35.390, or, before 
October 24, 2004, §§35.910, 35.920, or 
35.930, or equivalent Agreement State 
requirements, that the individual has 
satisfactorily completed the 
requirements in paragraph (c)(1) of this 
section and has achieved a level of 
competency sufficient to function 
independently as an authorized user for 
the medical uses authorized under 
§35.100.
 6. In §35.200, paragraph (b) is revised 
to read as follows:
§35.200 Use of unsealed byproduct 
material for imaging and localization 
studies for which a written directive is not 
required.
* * * * *
(b) Prepared by: 
(1) An authorized nuclear pharmacist; 
(2) A physician who is an authorized 
user and who meets the requirements 
specified in §§35.290, 35.390, or, before 
October 24, 2004, §35.920; or 
(3) An individual under the 
supervision, as specified in §35.27, of 
the authorized nuclear pharmacist in 
paragraph (b)(1) of this section or the 
physician who is an authorized user in 
paragraph (b)(2) of this section;
* * * * *
 7. In §35.290, paragraph (b), the 
introductory text of paragraph (c)(1)(ii), 
and paragraph (c)(2) are revised to read 
as follows:
§35.290 Training for imaging and 
localization studies.
* * * * *
(b) Is an authorized user under 
§35.390, or, before October 24, 2004, 
§35.920, or equivalent Agreement State 
requirements; or 
(c) * * * 
(1) * * * 
(ii) Work experience, under the 
supervision of an authorized user, who 
meets the requirements in §§35.290, 
35.390, or, before October 24, 2004, 
§35.920, or equivalent Agreement State 
requirements, involving—
* * * * *
(2) Has obtained written certification, 
signed by a preceptor authorized user 
who meets the requirements in 
§§35.290, 35.390, or, before October 24, 
2004, §35.920, or equivalent Agreement 
State requirements, that the individual 
has satisfactorily completed the 
requirements in paragraph (c)(1) of this 
section and has achieved a level of 
competency sufficient to function 
independently as an authorized user for 
the medical uses authorized under 
§§35.100 and 35.200.
 8. In §35.300, paragraph (b) is revised 
to read as follows:
§35.300 Use of unsealed byproduct 
material for which a written directive is 
required.
* * * * *
(b) Prepared by: 
(1) An authorized nuclear pharmacist; 
(2) A physician who is an authorized 
user and who meets the requirements 
specified in §§35.290, 35.390, or, before 
October 24, 2004, §35.920; or 
(3) An individual under the 
supervision, as specified in §35.27, of 
the authorized nuclear pharmacist in 
paragraph (b)(1) of this section or the 
physician who is an authorized user in 
paragraph (b)(2) of this section; or
* * * * *
 9. In §35.310, paragraph (a)(5) is 
revised to read as follows:
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§35.310 Safety instruction.
(a) * * * 
(5) Notification of the Radiation 
Safety Officer, or his or her designee, 
and an authorized user if the patient or 
the human research subject has a 
medical emergency or dies.
* * * * *
 10. In §35.315, paragraph (b) is revised 
to read as follows:
§35.315 Safety precautions.
* * * * *
(b) A licensee shall notify the 
Radiation Safety Officer, or his or her 
designee, and an authorized user as 
soon as possible if the patient or human 
research subject has a medical 
emergency or dies.
 11. In §35.390, the introductory text of 
paragraph (b)(1)(ii) and paragraph (b)(2) 
are revised to read as follows:
§35.390 Training for use of unsealed 
byproduct material for which a written 
directive is required. 
(b) * * * 
(1) * * * 
(ii) Work experience, under the 
supervision of an authorized user who 
meets the requirements in §§35.390(a), 
35.390(b), or, before October 24, 2004, 
§35.930, or equivalent Agreement State 
requirements. A supervising authorized 
user, who meets the requirements in 
§35.390(b) or, before October 24, 2004, 
§35.930(b), must also have experience 
in administering dosages in the same 
dosage category or categories (i.e., 
§35.390(b)(1)(ii)(G)(1), (2), (3), or (4)) as 
the individual requesting authorized 
user status. The work experience must 
involve—
* * * * *
(2) Has obtained written certification 
that the individual has satisfactorily 
completed the requirements in 
paragraph (b)(1) of this section and has 
achieved a level of competency 
sufficient to function independently as 
an authorized user for the medical uses 
authorized under §35.300. The written 
certification must be signed by a 
preceptor authorized user who meets 
the requirements in §§35.390(a), 
35.390(b), or, before October 24, 2004, 
§35.930, or equivalent Agreement State 
requirements. The preceptor authorized 
user, who meets the requirements in 
§35.390(b) or, before October 24, 2004, 
§35.930(b), must also have experience 
in administering dosages in the same 
dosage category or categories (i.e., 
§35.390(b)(1)(ii)(G)(1), (2), (3), or (4)) as 
the individual requesting authorized 
user status.
 12. In §35.392, paragraph (b), the 
introductory text of paragraph (c)(2), and 
paragraph (c)(3) are revised to read as fol-
lows:
§35.392 Training for the oral 
administration of sodium iodide I–131 
requiring a written directive in quantities 
less than or equal to 1.22 Gigabecquereis 
(33 millicuries).
* * * * *
(b) Is an authorized user under 
§§35.390(a), 35.390(b) for uses listed in 
§35.390(b)(1)(ii)(G)(1) or (2), §35.394, 
or, before October 24, 2004, §§35.930, 
35.932, or 35.934, or equivalent 
Agreement State requirements; or 
(c) * * * 
(2) Has work experience, under the 
supervision of an authorized user who 
meets the requirements in §§35.390(a), 
35.390(b), 35.392, 35.394, or, before 
October 24, 2004, §§35.930, 35.932, or 
35.934, or equivalent Agreement State 
requirements. A supervising authorized 
user who meets the requirements in 
§35.390(b), must also have experience 
in administering dosages as specified in 
§35.390(b)(1)(ii)(G)(1) or (2). The work 
experience must involve—
* * * * *
(3) Has obtained written certification 
that the individual has satisfactorily 
completed the requirements in 
paragraphs (c)(1) and (c)(2) of this 
section and has achieved a level of 
competency sufficient to function 
independently as an authorized user for 
medical uses authorized under §35.300. 
The written certification must be signed 
by a preceptor authorized user who 
meets the requirements in §§35.390(a), 
35.390(b), 35.392, 35.394, or, before 
October 24, 2004, §§35.930, 35.932, or 
35.934, or equivalent Agreement State 
requirements. A preceptor authorized 
user, who meets the requirement in 
§35.390(b), must also have experience 
in administering dosages as specified in 
§35.390(b)(1)(ii)(G)(1) or (2).
 13. In §35.394, paragraph (b), the 
introductory text of paragraph (c)(2), and 
paragraph (c)(3) are revised to read as fol-
lows:
§35.394 Training for the oral 
administration of sodium iodide I–131 
requiring a written directive in quantities 
greater than 1.22 Gigabecquereis (33 
millicuries).
* * * * *
(b) Is an authorized user under 
§§35.390(a), 35.390(b) for uses listed in 
§35.390(b)(1)(ii)(G)(2), or, before 
October 24, 2004, §§35.930 or 35.934, 
or equivalent Agreement State 
requirements; or 
(c) * * * 
(2) Has work experience, under the 
supervision of an authorized user who 
meets the requirements in §§35.390(a), 
35.390(b), 35.394, or, before October 24, 
2004, §§35.930 or 35.934, or equivalent 
Agreement State requirements. A 
supervising authorized user, who meets 
the requirements in §35.390(b), must 
also have experience in administering 
dosages as specified in 
§35.390(b)(1)(ii)(G)(2). The work 
experience must involve—
* * * * *
(3) Has obtained written certification 
that the individual has satisfactorily 
completed the requirements in 
paragraphs (c)(1) and (c)(2) of this 
section and has achieved a level of 
competency sufficient to function 
independently as an authorized user for 
medical uses authorized under §35.300. 
The written certification must be signed 
by a preceptor authorized user who 
meets the requirements in §§35.390(a), 
35.390(b), 35.394, or, before October 24, 
2004, §§35.930 or 35.934, or equivalent 
Agreement State requirements. A 
preceptor authorized user, who meets 
the requirements in §35.390(b), must 
also have experience in administering 
dosages as specified in 
§35.390(b)(1)(ii)(G)(2).
 14. In §35.432, paragraph (b) is revised 
to read as follows:
§35.432 Calibration measurements of 
brachytherapy sources.
* * * * *
(b) Instead of a licensee making its 
own measurements as required in 
paragraph (a) of this section, the 
licensee may use measurements 
provided by the source manufacturer or 
by a calibration laboratory accredited by 
the American Association of Physicists 
in Medicine that are made in 
accordance with paragraph (a) of this 
section.
* * * * *
 15. In §35.490, the introductory text of 
paragraph (b)(1)(ii), paragraphs (b)(2) 
and (b)(3) are revised to read as follows:
§35.490 Training for use of manual 
brachytherapy sources.
* * * * *
(b) * * * 
(1) * * * 
(ii) 500 hours of work experience, 
under the supervision of an authorized 
user who meets the requirements in 
§35.490, or, before October 24, 2004, 
§35.940, or equivalent Agreement State 
requirements at a medical institution, 
involving—
* * * * *
(2) Has obtained 3 years of supervised 
clinical experience in radiation 
oncology, under an authorized user who 
meets the requirements in §35.490, or, 
before October 24, 2004, §35.940, or 
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equivalent Agreement State 
requirements, as part of a formal 
training program approved by the 
Residency Review Committee for 
Radiation Oncology of the Accreditation 
Council for Graduate Medical Education 
or the Committee on Postdoctoral 
Training of the American Osteopathic 
Association. This experience may be 
obtained concurrently with the 
supervised work experience required by 
paragraph (b)(1)(ii) of this section; and 
(3) Has obtained written certification, 
signed by a preceptor authorized user 
who meets the requirements in §35.490, 
or, before October 24, 2004, §35.940, or 
equivalent Agreement State 
requirements, that the individual has 
satisfactorily completed the 
requirements in paragraphs (b)(1) and 
(b)(2) of this section and has achieved 
a level of competency sufficient to 
function independently as an 
authorized user of manual 
brachytherapy sources for the medical 
uses authorized under §35.400.
 16. In §35.491, paragraph (a), the 
introductory text of paragraph (b)(2), and 
paragraph (b)(3) are revised to read as fol-
lows:
§35.491 Training for ophthalmic use of 
strontium-90.
* * * * *
(a) Is an authorized user under 
§35.490, or, before October 24, 2004, 
§§35.940 or 35.941, or equivalent 
Agreement State requirements; or 
(b) * * * 
(2) Supervised clinical training in 
ophthalmic radiotherapy under the 
supervision of an authorized user at a 
medical institution, clinic, or private 
practice that includes the use of 
strontium-90 for the ophthalmic 
treatment of five individuals. This 
supervised clinical training must 
involve—
* * * * *
(3) Has obtained written certification, 
signed by a preceptor authorized user 
who meets the requirements in 
§§35.490, 35.491, or, before October 24, 
2004, §§35.940 or 35.941, or equivalent 
Agreement State requirements, that the 
individual has satisfactorily completed 
the requirements in paragraphs (a) and 
(b) of this section and has achieved a 
level of competency sufficient to 
function independently as an 
authorized user of strontium-90 for 
ophthalmic use.
 17. In §35.630, paragraph (a)(1) is 
revised to read as follows:
§35.630 Dosimetry equipment. 
(a) * * * 
(1) The system must have been 
calibrated using a system or source 
traceable to the National Institute of 
Standards and Technology (NIST) and 
published protocols accepted by 
nationally recognized bodies; or by a 
calibration laboratory accredited by the 
American Association of Physicists in 
Medicine (AAPM). The calibration must 
have been performed within the 
previous 2 years and after any servicing 
that may have affected system 
calibration; or
* * * * *
 18. In §35.690, the introductory text of 
paragraph (b)(1)(ii), and paragraphs 
(b)(2) and (b)(3) are revised to read as fol-
lows:
§35.690 Training for use of remote 
afterloader units, teletherapy units, and 
gamma stereotactic radiosurgery units.
* * * * *
(b) * * * 
(1) * * * 
(ii) 500 hours of work experience, 
under the supervision of an authorized 
user who meets the requirements in 
§35.690, or, before October 24, 2004, 
§35.960, or equivalent Agreement State 
requirements at a medical institution, 
involving—
* * * * *
(2) Has completed 3 years of 
supervised clinical experience in 
radiation oncology, under an authorized 
user who meets the requirements in 
§35.690, or, before October 24, 2004, 
§35.960, or equivalent Agreement State 
requirements, as part of a formal 
training program approved by the 
Residency Review Committee for 
Radiation Oncology of the Accreditation 
Council for Graduate Medical Education 
or the Committee on Postdoctoral 
Training of the American Osteopathic 
Association. This experience may be 
obtained concurrently with the 
supervised work experience required by 
paragraph (b)(1)(ii) of this section; and 
(3) Has obtained written certification 
that the individual has satisfactorily 
completed the requirements in 
paragraphs (b)(1) and (b)(2) of this 
section and has achieved a level of 
competency sufficient to function 
independently as an authorized user of 
each type of therapeutic medical unit 
for which the individual is requesting 
authorized user status. The written 
certification must be signed by a 
preceptor authorized user who meets 
the requirements in §35.690, or, before 
October 24, 2004, §35.960, or 
equivalent Agreement State 
requirements for an authorized user for 
each type of therapeutic medical unit 
for which the individual is requesting 
authorized user status.
 19. In §35.2432, paragraph (b)(5) is 
revised to read as follows:
§35.2432 Records of calibration 
measurements of brachytherapy sources.
* * * * *
(b) * * * 
(5) The name of the individual, the 
source manufacturer, or the calibration 
laboratory that performed the 
calibration.
Dated at Rockville, Maryland, this 31st day 
of March, 2003.
For the Nuclear Regulatory Commission. 
William D. Travers, 
Executive Director for Operations.
[FR Doc. 03–9601 Filed 4–18–03; 8:45 am] 
BILLING CODE 7590–01–P
DEPARTMENT OF TRANSPORTATION
Federal Aviation Administration 
14 CFR Part 39 
[Docket No. 2002–NM–73–AD; Amendment 
39–13122; AD 2003–08–10] 
RIN 2120–AA64 
Airworthiness Directives; Aerospatiale 
Model ATR42–500 Series Airplanes, 
and Model ATR72–102, –202, –212, and 
–212A Series Airplanes
AGENCY: Federal Aviation 
Administration, DOT.
ACTION: Final rule.
SUMMARY: This amendment adopts a 
new airworthiness directive (AD), 
applicable to certain Aerospatiale Model 
ATR42–500 series airplanes, and Model 
ATR72–102, –202, –212, and –212A 
series airplanes, that requires 
replacement of insulation blankets 
constructed of metallized 
polyethyleneteraphthalate (MPET) 
located from sections 11 through 16 of 
the fuselage with new insulation 
blankets constructed of Terul 18TM. This 
amendment is prompted by reports of 
in-flight and ground fires on certain 
airplanes manufactured with insulation 
blankets constructed of MPET, which 
may contribute to the spread of a fire 
when ignition occurs from small 
ignition sources such as electrical arcing 
or sparking. The actions specified by 
this AD are intended to ensure that 
insulation blankets constructed of 
MPET are removed from the fuselage. 
Such insulation blankets could 
propagate a small fire that is the result 
of an otherwise harmless electrical arc 
and could lead to a much larger fire. 
This action is intended to address the 
identified unsafe condition.
DATES: Effective May 27, 2003. 
The incorporation by reference of 
certain publications listed in the 
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